These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17016482)

  • 1. Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.
    Lane NE
    Nat Clin Pract Rheumatol; 2006 Oct; 2(10):562-9. PubMed ID: 17016482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in patients with systemic lupus erythematosus.
    García-Carrasco M; Mendoza-Pinto C; Escárcega RO; Jiménez-Hernández M; Etchegaray Morales I; Munguía Realpozo P; Rebollo-Vázquez J; Soto-Vega E; Delezé M; Cervera R
    Isr Med Assoc J; 2009 Aug; 11(8):486-91. PubMed ID: 19891237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of secondary osteoporosis.
    Kelman A; Lane NE
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1021-37. PubMed ID: 16301195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
    Compeyrot-Lacassagne S; Tyrrell PN; Atenafu E; Doria AS; Stephens D; Gilday D; Silverman ED
    Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis in systemic lupus erythematosus mechanisms.
    Lee C; Ramsey-Goldman R
    Rheum Dis Clin North Am; 2005 May; 31(2):363-85, viii. PubMed ID: 15922151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.
    Rhew EY; Lee C; Eksarko P; Dyer AR; Tily H; Spies S; Pope RM; Ramsey-Goldman R
    J Rheumatol; 2008 Feb; 35(2):230-6. PubMed ID: 18203323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis and systemic lupus erythematosus: etiology and treatment strategies.
    Segal LG; Lane NE
    Ann Med Interne (Paris); 1996; 147(4):281-9. PubMed ID: 8952749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors of osteoporosis in female SLE patients-extended report.
    Almehed K; Forsblad d'Elia H; Kvist G; Ohlsson C; Carlsten H
    Rheumatology (Oxford); 2007 Jul; 46(7):1185-90. PubMed ID: 17500075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDN-21 in premenopausal women with systemic lupus erythematosus treated with glucocorticoids.
    Navarro MA; Formiga F; Blanco A; Bonnin MR; Nolla JM; Moga I
    J Rheumatol; 1995 Dec; 22(12):2238-40. PubMed ID: 8835555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus.
    Fialho SC; Bonfá E; Vitule LF; D'Amico E; Caparbo V; Gualandro S; Pereira RM
    Lupus; 2007; 16(4):239-44. PubMed ID: 17439929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported fractures and associated factors in women with systemic lupus erythematosus.
    Lee C; Almagor O; Dunlop DD; Manzi S; Spies S; Ramsey-Goldman R
    J Rheumatol; 2007 Oct; 34(10):2018-23. PubMed ID: 17787041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of inflammation and vitamin D status in SLE-associated osteoporosis.
    Alele JD; Kamen DL
    Autoimmun Rev; 2010 Jan; 9(3):137-9. PubMed ID: 19427412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus.
    Gladman DD; Urowitz MB; Chaudhry-Ahluwalia V; Hallet DC; Cook RJ
    J Rheumatol; 2001 Apr; 28(4):761-5. PubMed ID: 11327247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteonecrosis in systemic lupus erythematosus. Report of 3 cases].
    Marrón A; Formiga F; Valverde J; Mitjavila F; Pac M; Moga I
    An Med Interna; 1997 Jun; 14(6):307-9. PubMed ID: 9410105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Sánchez-Guerrero J; Fragoso-Loyo HE; Neuwelt CM; Wallace DJ; Ginzler EM; Sherrer YR; McIlwain HH; Freeman PG; Aranow C; Petri MA; Deodhar AA; Blanton E; Manzi S; Kavanaugh A; Lisse JR; Ramsey-Goldman R; McKay JD; Kivitz AJ; Mease PJ; Winkler AE; Kahl LE; Lee AH; Furie RA; Strand CV; Lou L; Ahmed M; Quarles B; Schwartz KE
    J Rheumatol; 2008 Aug; 35(8):1567-75. PubMed ID: 18634158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orthopaedic manifestations of systemic lupus erythematosus.
    Egol KA; Jazrawi LM; DeWal H; Su E; Leslie MP; Di Cesare PE
    Bull Hosp Jt Dis; 2001; 60(1):29-34. PubMed ID: 11759575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
    Cruse LM; Valeriano J; Vasey FB; Carter JD
    J Clin Rheumatol; 2006 Oct; 12(5):221-5. PubMed ID: 17023807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis in systemic lupus erythematosus: prevention and treatment.
    Sen D; Keen RW
    Lupus; 2001; 10(3):227-32. PubMed ID: 11315358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity.
    Kiani AN; Magder L; Petri M
    J Rheumatol; 2008 Jul; 35(7):1300-6. PubMed ID: 18484694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.